PRGO: Perrigo Company PLC Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5,522.67
Enterprise Value ($M) 7,072.37
Book Value ($M) 5,104.50
Book Value / Share 37.94
Price / Book 1.08
NCAV ($M) -1,349.50
NCAV / Share -10.03
Price / NCAV -4.09

Profitability (mra)
Return on Invested Capital (ROIC) -0.01
Return on Assets (ROA) -0.01
Return on Equity (ROE) -0.02

Liquidity (mrq)
Quick Ratio 2.97
Current Ratio 4.01

Balance Sheet (mrq) ($M)
Current Assets 3,935.50
Assets 10,389.50
Liabilities 5,285.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 4,138.70
Operating Income 184.70
Net Income -68.90
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 156.30
Cash from Investing 1,275.80
Cash from Financing -178.70

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Price T Rowe Associates Inc /md/ 8.00 -5.36
02-10 13G/A Vanguard Group Inc 10.31 -9.81
02-03 13G/A BlackRock Inc. 8.60 13.99
01-10 13G Barrow Hanley Mewhinney & Strauss Llc 10.10

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2022-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended: April 2, 2022 ☐ TRANSITION REPORT PURSUANT TO S
2022-03-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI
2021-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended: October 2, 2021 ☐ TRANSITION REPORT PURSUANT TO
2021-08-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended: July 3, 2021 ☐ TRANSITION REPORT PURSUANT TO SE

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2022-06-28 114,963 1,036,132 11.10
2022-06-27 143,441 1,301,912 11.02
2022-06-24 96,661 1,554,705 6.22
2022-06-23 127,810 1,860,707 6.87

(click for more detail)

(click for list of largest short owners)

Similar Companies
OGN – Organon & Co. PBH – Prestige Brands Holdings, Inc.
PFE – Pfizer Inc. QGEN – QIAGEN N.V.
RCUS – Arcus Biosciences Inc


Financial data and stock pages provided by
Fintel.io